Call for Grant Applications (CGA)
Advances in Immuno-Oncology

I. Background

Pfizer - Independent Grants for Learning & Change (IGLC) and Merck KGaA, Darmstadt, Germany - Global Medical Education (GME) are collaborating to provide grant support for continuing professional education in the area of Immuno-Oncology. Immuno-Oncology is a top priority for Merck KGaA, Darmstadt, Germany, and Pfizer Inc. The global strategic alliance between our companies enables us to benefit from each other’s strengths and capabilities.

Through this CGA we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. The content or format of educational activities or related materials must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

II. Eligibility

| Geographic Scope: | North America: Canada, United States  
|                   | Europe: France, Germany, Italy, Spain, United Kingdom  
|                   | Asia/Pacific: Japan, Australia |

| Applicant Eligibility Criteria: | The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.  
|                               | Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, are encouraged. All partners must have a relevant role, and the requesting organization must have a leadership role. |
### III. Requirements

<table>
<thead>
<tr>
<th>Date CGA Issued:</th>
<th>April 4, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Area:</td>
<td>Immuno-Oncology</td>
</tr>
</tbody>
</table>

**Specific Area of Interest for this CGA:** Specifically within lung, bladder, ovarian, renal, skin, gastric, and/or head & neck cancers -

1. Increase understanding of the rationale for novel IO strategies such as anti-PD-1/PD-L1 therapy.
2. Increase awareness of when immunotherapy should be considered as a treatment option for patients to include patient selection, treatment sequencing, and drug combinations.
3. Improve ability to manage associated IO treatment issues including side effects and progression

The target learner audiences include: Medical Oncologists, Surgeons, Health System Pharmacists, Physician Assistants & Oncology Nurses.

All CME/CE activity types will be considered through this CGA including but not limited to; national or regional symposia, workshops, regional community series; online courses & tools, print materials and other enduring materials. Proposals may take a curriculum approach or have multiple components/activities.

Organizations are encouraged to describe their process for Continuous Assessment of their activities for both educational effectiveness as well as how they stay current when significant new data becomes available.


<table>
<thead>
<tr>
<th>Expected Approximate Monetary Range of Grant Applications:</th>
<th>The total available budget related to this CGA is approximately $800,000.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The typical grant maximum under this CGA will be up to $250,000. However larger proposals will be considered for funding if they include multiple activities such as several live events, enduring activities, and supportive materials and tools.</td>
</tr>
<tr>
<td></td>
<td>Smaller educational proposals are also encouraged. Organizations that would like to develop activities for a more limited regional or local group of healthcare providers should also apply. Typically grant amounts for local or regional activities should not exceed around $50,000 USD.</td>
</tr>
<tr>
<td></td>
<td>The grant amount Pfizer and Merck KGaA, Darmstadt, Germany will be prepared to fund will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.</td>
</tr>
</tbody>
</table>
### Key Dates:

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CGA release date</td>
<td>April 4, 2018</td>
</tr>
<tr>
<td>Grant application due date: May 31, 2018</td>
<td></td>
</tr>
<tr>
<td>Please note the deadline is midnight Eastern Time (New York, GMT -5).</td>
<td></td>
</tr>
<tr>
<td>Anticipated Grant Award Notification Date:</td>
<td>July 24, 2018</td>
</tr>
<tr>
<td>Grants distributed following execution of fully signed Letter of Agreement</td>
<td></td>
</tr>
<tr>
<td>Period of Performance: August 2018 to August 2020 (projects may be shorter; 24 month project maximum)</td>
<td></td>
</tr>
</tbody>
</table>

### How to Submit:

- Please go to the specific [application log-in page](#) and sign in. First-time users should click “REGISTER NOW”.
- Select the following Educational Area: CGA- 2018 Immuno-Oncology
- Requirements for submission:
  - Complete all required sections of the online application and upload the completed CGA template (see Appendix). If you encounter any technical difficulties with the grant management system, please click the “Need Support?” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed by the committee.

### Questions:

If you have questions regarding this CGA, please direct them in writing to Abdul Bhatti at [Abdul.Bhatti@pfizer.com](mailto:Abdul.Bhatti@pfizer.com), with the subject line “CGA-2018 Immuno-Oncology.”

### Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification or to make a summary presentation during the review period.

### IV. Terms and Conditions

Please take note every Call for Grant Applications (CGA) released by Pfizer Independent Grants for Learning & Change (IGLC) is governed by specific terms and conditions. These terms and conditions can be reviewed here: [http://www.pfizer.com/files/PfizerIGLC_CGA_TermsandConditions_2017Nov.pdf](http://www.pfizer.com/files/PfizerIGLC_CGA_TermsandConditions_2017Nov.pdf)
Appendix: CGA Grant Submission Template

Grant Applications should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

A. Title
B. Organizational Detail: Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each partner in the proposed project.
C. Goal: Briefly state the overall goal of the project.
D. Objectives: List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
E. Assessment of Need: Include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
F. Target Learner Audience: Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
G. Project Design and Methods: Describe the planned project, the educational approach, and the way the planned methods address the established need.
H. Innovation: Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.
I. Outcomes Evaluation: In terms of the metrics used for the needs assessment, describe how you will determine if the gap was addressed for the target group. Identify the sources of data you anticipate using to make the determination. Describe how you expect to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms of your target audience. Describe how you will determine if the target audience was fully engaged in the project.
J. Dissemination Plan: Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
K. Timeline
L. Additional Information: If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize it in within the page limitations.
M. References (outside the 15-page limit). There is no designated format for references
N. Budget (See template available in application). While estimating your budget please keep the following items in mind:
   - Grants awarded by IGLC cannot be used to purchase therapeutic agents (prescription or non-prescription).
   - Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for projects.
   - A separate Excel file should be uploaded. This does not count toward the page limit.
     - An example of the budget template can be found here: http://cybergrants.com/pfizer/docs/KnowledgeGapBudgetTemplate2015.xls
     - At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.